EP Patent

EP3447046A1 — Substituted biaryl sulfonamides and the use thereof

Assigned to Novomedix LLC · Expires 2019-02-27 · 7y expired

What this patent protects

Provided herein are substituted biaryl sulfonamide compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration o…

USPTO Abstract

Provided herein are substituted biaryl sulfonamide compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein modulate initiation of protein translation. In one embodiment, the compounds provided herein are used in combination with surgery, radiation therapy, immuno therapy and/or one or more additional anticancer drugs for the treatment, prevention, and/or amelioration of cancer and proliferative disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP3447046A1
Jurisdiction
EP
Classification
Expires
2019-02-27
Drug substance claim
No
Drug product claim
No
Assignee
Novomedix LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.